Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Finding the right balance between safety and returns isn’t easy, which is why StockStory is here to help. Keeping that in mind, here is one low-volatility stock providing safe-and-steady growth and two that may not deliver the returns you need.

Two Stocks to Sell:

Clorox (CLX)

Rolling One-Year Beta: 0.22

Founded in 1913 with bleach as the sole product offering, Clorox (NYSE: CLX) today is a consumer products giant whose product portfolio spans everything from bleach to skincare to salad dressing to kitty litter.

Why Do We Think Twice About CLX?

1. Products aren't resonating with the market as its revenue declined by 1.3% annually over the last three years
2. Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
3. Projected sales decline of 1.4% over the next 12 months indicates demand will continue deteriorating

Clorox is trading at $110.91 per share, or 17x forward P/E. Read our free research report to see why you should think twice about including CLX in your portfolio.

AdaptHealth (AHCO)

Rolling One-Year Beta: 0.56

With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ: AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders.

Why Does AHCO Fall Short?

1. Muted 2.1% annual revenue growth over the last two years shows its demand lagged behind its healthcare peers
2. Revenue growth over the past five years was nullified by the company’s new share issuances as its earnings per share fell by 1.3% annually
3. ROIC of 1.3% reflects management’s challenges in identifying attractive investment opportunities, and its decreasing returns suggest its historical profit centers are aging

At $10.55 per share, AdaptHealth trades at 12.4x forward P/E. Dive into our free research report to see why there are better opportunities than AHCO.

One Stock to Buy:

Kinsale Capital Group (KNSL)

Rolling One-Year Beta: 0.39

Founded in 2009 during the aftermath of the financial crisis when many insurers were retreating from riskier markets, Kinsale Capital Group (NYSE: KNSL) is an insurance company that specializes in writing policies for hard-to-place, unusual, or high-risk businesses that standard insurers typically avoid.

Why Are We Bullish on KNSL?

1. Market penetration was impressive this cycle as its net premiums earned expanded by 23.8% annually over the last two years
2. Balance sheet strength has increased this cycle as its 41.8% annual book value per share growth over the last two years was exceptional
3. Notable projected book value per share growth of 25.3% for the next 12 months hints at strong capital generation

Kinsale Capital Group’s stock price of $396.24 implies a valuation ratio of 4.5x forward P/B. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.

Stocks We Like Even More

Check out the high-quality names we’ve flagged in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.